CombiPatch and Climara Pro FDA Approval History: What Every Woman Should Know

What Are CombiPatch and Climara Pro, and Why Do They Exist?

Both patches deliver estradiol plus a progestogen through the skin, eliminating daily pills and first-pass liver metabolism. Women who still have a uterus require a progestogen alongside estradiol to protect the endometrium from hyperplasia and cancer. Combining both hormones in one patch improves adherence, because a twice-weekly or weekly change replaces two separate prescriptions.

CombiPatch delivers estradiol with norethindrone acetate (NETA). Climara Pro delivers estradiol with levonorgestrel (LNG). The two progestogens differ in androgenicity and metabolic footprint, which matters clinically when you have PCOS, acne-prone skin, or lipid concerns. NETA is more androgenic than micronized progesterone but less so than LNG on a receptor-affinity basis, though the clinical distinction between the two patches in everyday practice is modest.

Why Transdermal Delivery Changes the Risk Profile

Oral estrogen undergoes first-pass hepatic metabolism, raising clotting factors, triglycerides, and sex-hormone-binding globulin. Transdermal estradiol bypasses the liver almost entirely. Observational data from the French E3N cohort (over 80,000 women) suggest transdermal estradiol carries a lower venous thromboembolism (VTE) risk than oral estrogen 1. The FDA-approved labeling for both CombiPatch and Climara Pro still carries a VTE warning because the large randomized trials that established the class warning used oral combined HRT, not patches. This distinction between the label and the observational evidence is one you should discuss explicitly with your clinician.

The Uterine-Protection Rationale

Unopposed estrogen in a woman with a uterus increases endometrial cancer risk by approximately five-fold after five or more years of use. Adding a progestogen eliminates that excess risk when taken continuously. Both patches use continuous-combined dosing, meaning no withdrawal bleeds in most users after an initial spotting phase, which is the main reason postmenopausal women prefer them over sequential regimens.

CombiPatch FDA Approval: The Full Regulatory Timeline

CombiPatch received its original FDA approval on February 5, 1998 under NDA 020617. The original sponsor was Noven Pharmaceuticals, which licensed it to Novartis for US marketing under the brand name CombiPatch.

Pre-Approval Clinical Program

The key studies evaluated two dose combinations: 0.05 mg/day estradiol with 0.14 mg/day NETA (CombiPatch 0.05/0.14) and 0.05 mg/day estradiol with 0.25 mg/day NETA (CombiPatch 0.05/0.25). The lower-dose patch also comes in a 0.045 mg/day estradiol version depending on the formulation revision. The trials demonstrated statistically significant reductions in moderate-to-severe hot flush frequency versus placebo, and endometrial biopsy data confirmed adequate endometrial protection at both doses, a mandatory FDA requirement for any combined estrogen-progestogen product.

Post-Approval Label History: The WHI Effect

The most consequential label revision arrived in 2003 after the Women's Health Initiative (WHI) estrogen-plus-progestin arm was stopped early due to excess risk of invasive breast cancer, coronary heart disease events, stroke, and pulmonary embolism in women assigned to oral conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily 2. Although the WHI used oral MPA, not a transdermal norethindrone patch, the FDA applied a class-wide Black Box Warning to all estrogen-progestogen combination products, including CombiPatch.

The 2003 box warning stated:

"Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia." 3

This class action was scientifically debated because transdermal products were not studied in the WHI, but FDA concluded that the evidence was insufficient to carve out a safer class for patches at that time.

Subsequent Label Updates (2003-Present)

The CombiPatch label has been revised multiple times since 2003:

• 2004: Additional breast cancer risk language added, referencing the WHI breast cancer incidence data showing 8 additional cases per 10,000 women per year in the combined HRT arm versus placebo.
• 2007: Dosing guidance revised to recommend using the lowest effective dose for the shortest duration consistent with treatment goals, aligned with The Menopause Society (then NAMS) position statement 4.
• 2016: Updated cardiovascular risk language reflecting post-WHI sub-group analyses, clarifying that younger postmenopausal women (aged 50-59 or within 10 years of menopause) had different coronary risk profiles than older participants.
• 2022: Minor updates to align with current endometrial safety data.

Climara Pro FDA Approval: The Full Regulatory Timeline

Climara Pro received FDA approval on February 10, 2003 under NDA 021168. The sponsor was Berlex Laboratories, later acquired by Bayer HealthCare. The patch delivers 0.045 mg/day estradiol and 0.015 mg/day levonorgestrel, changed once weekly.

What Made Climara Pro Distinct at Approval

Climara Pro entered a market already shaped by WHI anxiety. Its approval came just months before the full WHI manuscript appeared in JAMA. Bayer's clinical program emphasized:

1. Weekly rather than twice-weekly application (versus CombiPatch's twice-weekly schedule), which was a meaningful adherence advantage.
2. A lower progestogen dose, because LNG is more potent than NETA milligram-for-milligram.
3. Osteoporosis prevention as a co-primary endpoint, supported by bone mineral density (BMD) data showing significant improvement at the lumbar spine and hip versus placebo.

The osteoporosis prevention indication was particularly relevant given that approximately 50% of postmenopausal women will experience an osteoporosis-related fracture over their lifetime.

Climara Pro Label History

Because Climara Pro was approved in 2003, it launched with the WHI-informed Black Box Warning already incorporated. Its label has since been updated to:

• Clarify that the product is not for use in women with an intact uterus who require higher endometrial protection (some women on Climara Pro still need additional progestogen assessment).
• Include updated VTE risk language following European observational studies suggesting lower absolute VTE rates with transdermal versus oral preparations, while maintaining the class warning.
• Reflect the 2022 NAMS position statement recommendation that for healthy women under 60 within 10 years of menopause onset, the benefits of HRT for vasomotor symptoms generally outweigh the risks 4.

What the Current Labels Actually Say: Side by Side

Both labels share the same Black Box Warning class language, but the approved doses, change schedules, and progestogen types differ in ways that matter clinically.

| Feature | CombiPatch | Climara Pro | |---|---|---| | Estradiol dose | 0.05 mg/day | 0.045 mg/day | | Progestogen | NETA 0.14 or 0.25 mg/day | LNG 0.015 mg/day | | Change schedule | Twice weekly | Once weekly | | Approved indications | VMS, osteoporosis prevention | VMS, osteoporosis prevention | | Endometrial cancer risk reduction | Yes (with intact uterus) | Yes (with intact uterus) | | Pregnancy | Contraindicated (Category X) | Contraindicated (Category X) | | Breast cancer box warning | Yes (class) | Yes (class) |

What the Label Does Not Say (and Why That Matters)

The label is a floor, not a ceiling for clinical knowledge. Neither label accounts for the post-2010 observational literature distinguishing transdermal from oral estrogen on VTE and stroke risk. A 2019 analysis in the BMJ found that transdermal estradiol was not associated with increased VTE risk while oral estrogen was, a finding not yet incorporated into the FDA label language. Your clinician should factor this into your shared decision-making, even though the label has not caught up.

Sex-Specific Physiology: How the Hormonal Life Stage Changes Everything

Neither patch is appropriate at every life stage. Here is how your reproductive status changes what is safe and what is indicated.

Reproductive Years (Before Menopause)

These patches are not indicated for premenopausal women. Both products contain progestogen doses calibrated to protect a postmenopausal endometrium, not to suppress ovulation reliably. A woman in her 30s with PCOS or heavy periods who needs hormonal management should be on a different regimen entirely. Using CombiPatch or Climara Pro in reproductive-age women would expose them to inadequate contraceptive protection and inappropriate hormone levels for their endogenous background.

Perimenopause

Perimenopause presents the trickiest prescribing window. Ovarian function is erratic. Estradiol levels can still spike to premenopausal values intermittently. Neither patch is FDA-approved for perimenopausal use as labeled, yet many clinicians prescribe transdermal estradiol for hot flushes during perimenopause. If you are perimenopausal and not yet clearly postmenopausal, a reliable contraceptive method is still required if you do not want to conceive, because these patches do not reliably suppress ovulation.

A practical rule many menopause specialists use: women who have been amenorrheic for 12 consecutive months (the standard clinical definition of menopause) are appropriate candidates for combined patches if symptomatic. Before 12 months, proceed with caution and reliable contraception.

Postmenopause (The Approved Population)

Postmenopausal women aged 50-59 with bothersome vasomotor symptoms and no contraindications represent the core approved population. The Menopause Society's 2022 position statement notes that for this group, the absolute risks of HRT are low and the quality-of-life benefits can be substantial. Women more than 10 years past menopause or over 60 face a different benefit-risk calculation, particularly for coronary disease, and the label reflects that uncertainty.

Surgical Menopause

Women who have had a bilateral oophorectomy before natural menopause face an abrupt, severe estrogen drop. They often have more intense hot flushes and are at higher risk of accelerated bone loss. For women who also have an intact uterus after hysterectomy plus oophorectomy (less common but possible), a combined patch remains appropriate. Women who had a hysterectomy along with oophorectomy do not need the progestogen component and should consider estradiol-only patches.

Pregnancy and Lactation Safety: A Required Conversation

Pregnancy: Contraindicated

Both CombiPatch and Climara Pro carry FDA Pregnancy Category X. This means animal or human data show fetal risk that clearly outweighs any possible benefit. Exogenous estrogen-progestogen combinations in early pregnancy are associated with congenital defects including cardiovascular and limb abnormalities in animal models. Human epidemiological data do not definitively establish teratogenicity from brief inadvertent exposure, but deliberate use is unjustifiable.

If you discover you are pregnant while using either patch, remove the patch immediately and contact your obstetric provider.

The Contraception Requirement

Because a perimenopausal woman may still ovulate, anyone who is not clearly postmenopausal (12 consecutive months without a period) and who is using transdermal HRT for symptom management should use a reliable, non-hormonal contraceptive method or a hormonal method specifically approved for contraception. These patches are not contraceptives. They will not reliably prevent pregnancy in a woman who is still ovulating.

Lactation

Neither patch is indicated postpartum. Exogenous estrogen suppresses prolactin and can substantially reduce milk supply, particularly in the first six weeks postpartum. Postpartum hot flushes from lactational estrogen suppression are physiological and generally resolve without treatment. If postpartum symptoms are severe, a lactation medicine specialist or OB-GYN should be consulted before initiating any HRT. Norethindrone acetate and levonorgestrel do transfer into breast milk in small amounts 5, though the clinical significance for nursing infants at postmenopausal doses has not been studied because these patches are not used in that population.

Who This Is Right For and Who Should Avoid It

Potentially a Good Fit

• Postmenopausal women with moderate-to-severe hot flushes who have not found relief from lifestyle changes
• Women with an intact uterus who need endometrial protection alongside estradiol
• Women who prefer once-weekly (Climara Pro) or twice-weekly (CombiPatch) patch changes over daily pills
• Women with triglyceride concerns, since transdermal estrogen does not raise triglycerides the way oral estrogen does
• Women at elevated fracture risk who want osteoporosis prevention alongside symptom relief

Likely Not a Good Fit

• Women with active or recent breast cancer or a BRCA mutation history (discuss carefully with oncology)
• Women with a personal history of VTE or stroke, where even transdermal estrogen carries meaningful uncertainty
• Women with unexplained vaginal bleeding (rule out endometrial pathology first)
• Premenopausal women, perimenopausal women who still need contraception, or anyone trying to conceive
• Women with active liver disease (transdermal avoids first-pass, but liver disease is still a label contraindication)
• Women who have had a hysterectomy (use estradiol-only patches; progestogen is not needed and adds risk without benefit)

Post-Market Surveillance and Ongoing Safety Monitoring

The FDA uses the Sentinel System, its active surveillance network covering more than 100 million insured Americans, to monitor post-market signals for approved drugs. No new safety signals specific to CombiPatch or Climara Pro transdermal patches have prompted label changes beyond the class-wide WHI-derived updates. The FDA Sentinel program continues to track estrogen-progestogen combination products as a class.

European regulators through the EMA have taken a somewhat different position, acknowledging more explicitly in EPAR documents that transdermal routes may carry lower thrombotic risk than oral routes, though the EMA similarly has not formally separated patch products from the class warning for all risk categories.

The continuous combined transdermal approach to postmenopausal HRT was evaluated in a 2004 meta-analysis covering over 1,400 women, which confirmed acceptable endometrial safety and hot flush efficacy across multiple transdermal regimens 6. That analysis remains foundational to understanding how combination patches compare to oral HRT in terms of bleeding profiles and endometrial outcomes.

The Evidence Gap for Women: What We Still Do Not Know

Women have been historically under-represented in cardiovascular and oncology trials, and HRT research is no exception. The WHI enrolled largely older women (mean age 63) who were more than a decade past menopause, a population very different from the typical 52-year-old presenting with hot flushes. Applying WHI risk estimates to younger, recently menopausal women is an extrapolation, not a direct measurement.

No large randomized controlled trial has directly compared transdermal combination patches to oral combined HRT on cardiovascular endpoints in women aged 50-59. The observational data suggest lower VTE and stroke risk with transdermal estrogen, but that evidence comes from non-randomized cohorts and cannot fully control for healthy-user bias. Clinicians who counsel you about these patches should be transparent about which statements are based on randomized data and which are based on observational extrapolation.

The ACOG Practice Bulletin on hormone therapy acknowledges this uncertainty explicitly, noting that "differences in routes of administration may affect the risk profile" while stopping short of recommending transdermal over oral for all women 7.

Practical Prescribing Snapshot: Doses and Application

CombiPatch:

• Available as 9 cm² patch (0.05/0.14) and 16 cm² patch (0.05/0.25)
• Apply to lower abdomen below the waistline, rotating sites
• Change every 3 to 4 days (twice weekly)
• Do not apply to breasts or waistline where clothing causes friction

Climara Pro:

• Single patch size delivering 0.045 mg/day E2 and 0.015 mg/day LNG
• Apply to lower abdomen
• Change once weekly
• Remove old patch before applying new one

Both patches should be applied to clean, dry, intact skin. Swimming and bathing are generally fine; patch adhesion studies confirm adequate drug delivery with normal bathing habits. If a patch falls off, reapply if still within the dosing window, or apply a new patch and maintain the original change-day schedule.

Start at the lowest dose that controls symptoms. Most guidelines recommend reassessing the need for continued therapy at least annually.